Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Shares Issued (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Shares Issued for 3 consecutive years, with -$136.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued changed N/A to -$136.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 92.96% year-over-year, with the annual reading at $1.3 million for FY2025, 92.96% down from the prior year.
  • Shares Issued hit -$136.7 million in Q4 2025 for Compass Therapeutics, down from $138.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $138.0 million in Q3 2025 to a low of -$136.7 million in Q4 2025.
  • Historically, Shares Issued has averaged $3.6 million across 3 years, with a median of $3.0 million in 2023.
  • Biggest YoY gain for Shares Issued was 99.57% in 2024; the steepest drop was 99.57% in 2024.
  • Year by year, Shares Issued stood at $3.1 million in 2023, then crashed by 99.58% to $13000.0 in 2024, then plummeted by 1051823.08% to -$136.7 million in 2025.
  • Business Quant data shows Shares Issued for CMPX at -$136.7 million in Q4 2025, $138.0 million in Q3 2025, and $13000.0 in Q2 2024.